Advanced Search

Ordinance On Corporate Disclosure Of Diacetylmorphin To Treatment Centers For Drug Addicts

Original Language Title: Bekendtgørelse om virksomheders udlevering af diacetylmorphin til behandlingssteder for stofmisbrugere

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now for only USD$40 per month.
Table of Contents

Publication of the delivery of diacetylmorphin of the diacetylmorphin of drug addicts

In accordance with paragraph 29, paragraph 1. 3, section 60, paragraph. 4, section 84, paragraph. 4 and Section 104 (3). 3 in Law No 1180 of 12. In December 2005 on medicinal products, as amended by law no. 1557 of 20. December 2006 and Law No 534 of 17. June 2008, the following shall be :

Scope of application

§ 1. This notice shall include those undertakings which, pursuant to Article 7 (2), shall apply to : 1, in the proclamations of euphoria, the medical board has received the consent of the Medicinal Board to negotiate and extradite diacetylmorphin to the municipal, regional and private treatment sites referred to in the health services section 142 of the health services.

Conditions for the delivery of diacetylmorphin of diacetylmorphin

§ 2. The company may only negotiate and deliver diacetylmorphin if a written order note is available from a medical officer approved by the Board of Health to prescribe diacetylmorphin for substance abuse.

Paragraph 2. The company must keep the order note at the address for 2 years.

Paragraph 3. The company must only expand the order note once.

Requirement Note Requirements

§ 3. The company may express an order only if it is provised, the signature of the doctor, printed or stamped, information on the doctor's name, no. and the authorization ID, and the telephone number, SKS code. Equine. and address of the treatment facility.

Paragraph 2. The company may deselect the order ' s order if it contains information on the medicinal product's name, the medicinal product, strength (if the medicinal product is available in several strengths) and quantity. Strength and quantity must be clearly stated (in terms of numbers and in letters) and in a way that changes cannot be made.

Paragraph 3. Where diacetylmorphin has not issued a marketing authorisation of the Medicinal Products Agency or a Community marketing authorisation or marketed diacetylmorphin not in Denmark, the company must ensure that there is a the delivery permit, cf. Article 29 (4) of the medicinal product. 1.

Documentation for Expedition

§ 4. The company must ensure that workflows and routines enable it to be resolved for at least three months after the expedition of the order note can be found in the expedition of the expedition.

§ 5. The company must provide the medicinal product with the company name and date of the expedition.

Deliver

§ 6. The company must provide diacetylmorphin to the processing sites referred to in section 1.

Reporting of information on turnover

§ 7. The undertaking shall, in accordance with the rules laid down in the publication of information on the circulation of products and so forth, etc., months, months, months, and so forth, in machine-readable position to the Medicinal Board for the Medicinal Products for Sales and so on by diacetylmorphin.

Pensation

§ 8. In exceptional cases and under conditions laid down in each individual case, the Danish Agency may dispense with the provisions of this notice or to make stricter requirements.

Penalty provisions

§ 9. With fine punishment, the person violating § § 2-7.

Paragraph 2. Companies can be imposed on companies, etc. (legal persons) punishable by the rules of the penal code 5. Chapter.

Entry into force

§ 10. The announcement shall enter into force on the 15th. May 2009.

The medical board, the 11th. May 2009 Jytte Lyngvig/Anne-Marie Vangsted